Activation of PP2A as druggable target in HCC therapy

Background: Hepatocellular carcinoma (HCC) is one of the most common solid tumor entities worldwide and the third leading cause of cancer related death. For advanced stage disease, systemic pharmacotherapy is the only established therapy, targeting the oncogenic protein kinases pathways. However, chemotherapy still yields poor response rates and survival in those patients. Recently, it could be demonstrated, that activating the protein phosphatase pathways may have a therapeutic impact on various types of cancer. Methods: The murine and human HCC cell lines Hepa 1 – 6, Hepa 129, HuH7, HepG2 and Hep3B were used f…